Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1805 1
1952 1
1953 1
1988 1
1991 2
1993 1
1996 1
1999 1
2000 1
2001 2
2003 4
2008 4
2009 6
2010 14
2011 19
2012 32
2013 32
2014 27
2015 41
2016 64
2017 49
2018 34
2019 51
2020 37
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 26077004

378 results
Results by year
Filters applied: . Clear all
Page 1
Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population.
Uvirova M, Simova J, Kubova B, Dvorackova N, Tomaskova H, Sedivcova M, Dite P. Uvirova M, et al. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015 Sep;159(3):466-71. doi: 10.5507/bp.2015.029. Epub 2015 Jun 11. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015. PMID: 26077004 Free article.
A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy.
Saridaki Z, Weidhaas JB, Lenz HJ, Laurent-Puig P, Jacobs B, De Schutter J, De Roock W, Salzman DW, Zhang W, Yang D, Pilati C, Bouché O, Piessevaux H, Tejpar S. Saridaki Z, et al. Clin Cancer Res. 2014 Sep 1;20(17):4499-4510. doi: 10.1158/1078-0432.CCR-14-0348. Clin Cancer Res. 2014. PMID: 25183481 Free PMC article.
Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab.
Kjersem JB, Ikdahl T, Guren T, Skovlund E, Sorbye H, Hamfjord J, Pfeiffer P, Glimelius B, Kersten C, Solvang H, Tveit KM, Kure EH. Kjersem JB, et al. BMC Cancer. 2012 Nov 20;12:534. doi: 10.1186/1471-2407-12-534. BMC Cancer. 2012. PMID: 23167843 Free PMC article. Clinical Trial.
A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer.
Smits KM, Paranjape T, Nallur S, Wouters KA, Weijenberg MP, Schouten LJ, van den Brandt PA, Bosman FT, Weidhaas JB, van Engeland M. Smits KM, et al. Clin Cancer Res. 2011 Dec 15;17(24):7723-31. doi: 10.1158/1078-0432.CCR-11-0990. Epub 2011 Oct 12. Clin Cancer Res. 2011. PMID: 21994416 Free PMC article.
The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients.
Sebio A, Paré L, Páez D, Salazar J, González A, Sala N, del Río E, Martín-Richard M, Tobeña M, Barnadas A, Baiget M. Sebio A, et al. Pharmacogenet Genomics. 2013 Mar;23(3):142-7. doi: 10.1097/FPC.0b013e32835d9b0b. Pharmacogenet Genomics. 2013. PMID: 23324806
Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan.
Graziano F, Canestrari E, Loupakis F, Ruzzo A, Galluccio N, Santini D, Rocchi M, Vincenzi B, Salvatore L, Cremolini C, Spoto C, Catalano V, D'Emidio S, Giordani P, Tonini G, Falcone A, Magnani M. Graziano F, et al. Pharmacogenomics J. 2010 Oct;10(5):458-64. doi: 10.1038/tpj.2010.9. Epub 2010 Feb 23. Pharmacogenomics J. 2010. PMID: 20177422 Free article. Clinical Trial.
Let-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysis.
Langevin SM, Christensen BC. Langevin SM, et al. Cancer Med. 2014 Oct;3(5):1385-95. doi: 10.1002/cam4.279. Epub 2014 Jun 2. Cancer Med. 2014. PMID: 24890702 Free PMC article. Review.
High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease.
Ruzzo A, Graziano F, Vincenzi B, Canestrari E, Perrone G, Galluccio N, Catalano V, Loupakis F, Rabitti C, Santini D, Tonini G, Fiorentini G, Rossi D, Falcone A, Magnani M. Ruzzo A, et al. Oncologist. 2012;17(6):823-9. doi: 10.1634/theoncologist.2012-0081. Epub 2012 May 14. Oncologist. 2012. PMID: 22584434 Free PMC article.
Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial).
Sha D, Lee AM, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Diasio RB. Sha D, et al. Clin Cancer Res. 2014 Jun 15;20(12):3319-27. doi: 10.1158/1078-0432.CCR-14-0069. Epub 2014 Apr 11. Clin Cancer Res. 2014. PMID: 24727325 Free PMC article. Clinical Trial.
EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients.
Villalva C, Duranton-Tanneur V, Guilloteau K, Burel-Vandenbos F, Wager M, Doyen J, Levillain PM, Fontaine D, Blons H, Pedeutour F, Karayan-Tapon L. Villalva C, et al. Cancer Med. 2013 Jun;2(3):296-304. doi: 10.1002/cam4.82. Epub 2013 Apr 23. Cancer Med. 2013. PMID: 23930206 Free PMC article.
378 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback